MedDataX Logo

Text Messaging and Atopic Dermatitis

NCT ID: NCT01216059

Last Updated: 2012-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2012-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atopic dermatitis is a common problem faced by patients of all ages and backgrounds. Treatment regimens and specific therapies may be time consuming and multiple studies have documented a parallel decrease in compliance as time after an office visit increases. The adolescent population is an extremely challenging sub-group of patients in terms of complying with a treatment regimen. Not only are they striving for independence and thus lacking supervision of a regimen by a parent, but their complex thinking skills are immature, leading to forgetful behavior. By introducing a reminder system for these vulnerable patients that is easily incorporated into their daily lives, the investigators propose that patients will have better compliance at applying their medication and thus improving their atopic dermatitis. Text-messaging via cell phones has become very popular among teenagers and adults and provides a non-obtrusive method of sending a treatment reminder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We propose to conduct a randomized, controlled 6-week trial to evaluate the impact of a text message-based reminder program on adherence to health maintenance behaviors among adolescents diagnosed with Atopic Dermatitis. After obtaining informed consent, subjects will be randomized into either an intervention or control group. Subjects in the intervention group will receive a daily text message with a tailored message regarding atopic dermatitis, while control group subjects will receive a weekly text message with information on local weather, sport or news without any reference to atopic dermatitis. Of note, the decision to send a weekly text message to the control group reflects the expectation that a message will be sent, although the frequency and content of the message will not be revealed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atopic Dermatitis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

adherence text message reminder adolescents

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

Subjects will receive daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study.

Group Type EXPERIMENTAL

Text message to cell phone

Intervention Type PROCEDURE

Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study

Control Group

Subjects will receive a weekly text message reminder about pop-culture, sports or weather.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Text message to cell phone

Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 10-17 inclusive
* Capable of giving informed consent/assent. Of note, all subjects will sign an assent form and parents will sign a parent consent form.
* Diagnosed with Atopic Dermatitis by a physician (self report)
* IGA score fo 2 or greater
* Currently using at least one prescribed topical therapy for atopic dermatitis
* Have a mobile phone capable of receiving text messages
* Able to retrieve text messages from mobile phone
* Able to adhere to study visit schedule and other protocol requirements.

Exclusion Criteria

* Younger than 10 years of age or 18 years and older at the time of enrollment
* No diagnosis of atopic dermatitis by a physician
* IGA score of 0 or 1
* Currently on no prescribed topical treatment for atopic dermatitis
* UV therapy or climatotherapy is a part of treatment for atopic dermatitis
* Does not have a mobile phone capable of receiving text messages
* Unable to retrieve text message
* Non-English speaking individuals (text messages are in English)
Minimum Eligible Age

10 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Northwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Amy Paller

Professor and Chair of Department of Dermatology, Professor of Pediatrics

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Amy Paller, MD

Role: PRINCIPAL_INVESTIGATOR

Northwestern University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northwestern University Feinberg School of Medicine, Department of Dermatology

Chicago, Illinois, United States

Site Status

Children's Memorial Hospital

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

STU29486

Identifier Type: -

Identifier Source: org_study_id